MedTrace Logo

To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets

NCT00946790 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of hydroxychloroquine sulfate, 200 mg tablets.

Conditions

  • Immunosuppression
  • Rheumatism

Interventions

DRUG

Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)

DRUG

Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)

Sponsors & Collaborators

Principal Investigators

  • Gerald Gantt, M.D. · PharmaKinetics Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1993-07-31
Primary Completion
1993-12-31
Completion
1993-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00946790 on ClinicalTrials.gov